The Iowa Continuity of Care study: Background and methods.

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
B L CarterJohn M Brooks

Abstract

The background and methods of an ongoing study to determine the effects of hospital pharmacists' enhanced communication with patients and their community providers are described. The Iowa Continuity of Care study is a randomized, prospective trial enrolling 1000 patients with selected medical conditions admitted to one large Midwest hospital. Patients will be randomized to a control group (usual care), minimal intervention, or enhanced intervention. For the intervention groups, a pharmacist case manager (PCM) will provide admission medication verification with the patients' community pharmacists, medication teaching, and discharge counseling. Patients in the enhanced intervention group will have a discharge care plan faxed to their outpatient physician and community pharmacist and will receive a follow-up phone call from the PCM three to five days after discharge; the PCM will continue to facilitate communication between the patient and community providers until all medication problems are resolved. A blinded research nurse will collect data, including adverse drug event (ADE) data, at admission and 30 and 90 days after discharge. The primary outcome measures include medication appropriateness, ADEs, emergency department visits...Continue Reading

References

Jan 1, 1976·International Journal of Health Services : Planning, Administration, Evaluation·S Katz, C A Akpom
Dec 1, 1992·American Journal of Public Health·S SheaC K Francis
Oct 1, 1992·Journal of Clinical Epidemiology·J T HanlonJ R Feussner
Jun 1, 1987·Archives of Internal Medicine·T J IvesR E Gwyther
Feb 1, 1974·Journal of Abnormal Psychology·A BanduraC L Wright
Oct 1, 1984·Drug Intelligence & Clinical Pharmacy·B L CarterC A Waterbury
Aug 1, 1981·Clinical Pharmacology and Therapeutics·C A NaranjoD J Greenblatt
Oct 9, 1995·Archives of Internal Medicine·J A Johnson, J L Bootman
Jul 5, 1995·JAMA : the Journal of the American Medical Association·D W BatesR Hallisey
Jan 1, 1996·European Journal of Clinical Pharmacology·W HimmelM M Kochen
Oct 1, 1996·The Annals of Pharmacotherapy·J M Ruscin, T P Semla
Jan 22, 1997·JAMA : the Journal of the American Medical Association·D W BatesL L Leape
Jan 1, 1997·Journal of Clinical Epidemiology·J F Steiner, A V Prochazka
Aug 1, 1997·British Journal of Clinical Pharmacology·L SmithH Chrystyn
Jan 23, 1998·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·B L CarterS J Billups
Jun 2, 1998·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·A K KuehlB A Sorofman
Jul 29, 1998·The Annals of Pharmacotherapy·R E GrymonpreD S Sitar
May 20, 1999·Pharmacotherapy·C A BondT Franke
Jul 28, 1999·JAMA : the Journal of the American Medical Association·L L LeapeD W Bates
Nov 5, 1999·Archives of Internal Medicine·S T McMullinT C Bailey
Sep 1, 2000·The American Journal of Medicine·J H GurwitzD W Bates
Oct 17, 2001·Annals of Internal Medicine·E L Knight, J Avorn
Jan 16, 2002·The American Journal of Medicine·V DudasS Z Pantilat
Nov 21, 2002·American Journal of Hypertension·Barry L CarterElizabeth Chrischilles
Jan 14, 2003·Pharmacotherapy·Glen T SchumockUNKNOWN 2002 Task Force on Economic Evaluation of Clinical Pharmacy Services of the American College of Clinical Pharmacy
Feb 1, 2003·Annals of Internal Medicine·Alan J ForsterDavid W Bates
Mar 8, 2003·JAMA : the Journal of the American Medical Association·Jerry H GurwitzDavid W Bates
Apr 18, 2003·The New England Journal of Medicine·Tejal K GandhiDavid W Bates
Sep 21, 1963·JAMA : the Journal of the American Medical Association·S KATZM W JAFFE
Nov 25, 2003·Journal of the American Pharmacists Association : JAPhA·Chris Bradberry, Marialice Bennett
Jun 12, 2004·Journal of the American Pharmacists Association : JAPhA·Elizabeth A ChrischillesAngela K Kuehl
Oct 20, 2005·Pharmacotherapy·Barbara J ZarowitzEdward L Peterson
Mar 15, 2006·Archives of Internal Medicine·Jeffrey L SchnipperDavid W Bates
May 10, 2006·Archives of Internal Medicine·Peter J KaboliJeffrey L Schnipper

❮ Previous
Next ❯

Citations

Mar 12, 2010·American Journal of Pharmaceutical Education·Gayle A BrazeauAndrew P Traynor
Feb 12, 2014·International Journal of Clinical Pharmacy·T Michael FarleyBarry L Carter
Sep 23, 2014·BMC Health Services Research·Karen B FarrisJohn M Brooks
Apr 14, 2012·The Annals of Pharmacotherapy·Gary R MatzkeJanet A Silvester
Apr 14, 2012·The Annals of Pharmacotherapy·Gary R Matzke
Oct 8, 2014·The Cochrane Database of Systematic Reviews·Susan M PattersonCarmel Hughes
Jun 15, 2011·The Annals of Pharmacotherapy·Leigh Ann Ross
May 4, 2018·Basic & Clinical Pharmacology & Toxicology·Helene Skjøt-ArkilTrine Graabaek
Aug 24, 2018·The Cochrane Database of Systematic Reviews·Patrick RedmondTom Fahey
Dec 21, 2016·Journal of the American Heart Association·Barry L Carter, Gail Ardery
Aug 31, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Emily N IsraelBarry L Carter
Jan 28, 2016·The Cochrane Database of Systematic Reviews·Daniela C Gonçalves-BradleySasha Shepperd
Mar 13, 2017·International Journal of Clinical Pharmacy·Choon Ean OoiRohan A Elliott
May 31, 2018·Pharmacy : Journal of Pharmacy, Education and Practice·Morten Baltzer HoulindLene Juel Kjeldsen
Oct 23, 2019·BMC Health Services Research·Fatma Karapinar-ÇarkıtPatricia M L A van den Bemt

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
C Michael White, Lauren Schlesselmann
Journal of Cardiac Failure
Heart Failure Society Of America
© 2022 Meta ULC. All rights reserved